RT Journal Article
T1 Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.
A1 Magnano, Laura
A1 Alonso-Alvarez, Sara
A1 Alcoceba, Miguel
A1 Rivas-Delgado, Alfredo
A1 Muntañola, Anna
A1 Nadeu, Ferran
A1 Setoain, Xavier
A1 Rodríguez, Sonia
A1 Andrade-Campos, Marcio
A1 Espinosa-Lara, Natalia
A1 Rodríguez, Guillermo
A1 Sancho, Juan Manuel
A1 Moreno, Miriam
A1 Mercadal, Santiago
A1 Carro, Itziar
A1 Salar, Antonio
A1 Garcia-Pallarols, Francesc
A1 Arranz, Reyes
A1 Cannata, Jimena
A1 Terol, María J
A1 Teruel, Ana I
A1 Jiménez-Ubieto, Ana
A1 Rodriguez, Antonia
A1 González de Villambrosía, Sonia
A1 Bello, José L
A1 López, Lourdes
A1 Novelli, Silvana
A1 de Cabo, Erik
A1 Infante, María E
A1 Pardal, Emilia
A1 Monsalvo, Silvia
A1 González, Marcos
A1 Martín, Alejandro
A1 Caballero, M Dolores
A1 López-Guillermo, Armando
A1 Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO), 
K1 complete response
K1 follicular lymphoma
K1 survival
AB The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL). Recently, complete response at 30 months (CR30) has been suggested as a surrogate for progression-free survival. This study aimed to analyse the life expectancy of FL patients according to their status at 30 months from the start of treatment in comparison with the sex and age-matched Spanish general population (relative survival; RS). The training series comprised 263 patients consecutively diagnosed with FL in a 10-year period who needed therapy and were treated with rituximab-containing regimens. An independent cohort of 693 FL patients from the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO) group was used for validation. In the training cohort, 188 patients were in CR30, with a 10-year overall survival (OS) of 53% and 87% for non-CR30 and CR30 patients, respectively. Ten-year RS was 73% and 100%, showing no decrease in life expectancy for CR30 patients. Multivariate analysis indicated that the FL International Prognostic Index was the most important variable predicting OS in the CR30 group. The impact of CR30 status on RS was validated in the independent GELTAMO series. In conclusion, FL patients treated with immunochemotherapy who were in CR at 30 months showed similar survival to a sex- and age-matched Spanish general population.
YR 2019
FD 2019-02-22
LK http://hdl.handle.net/10668/13606
UL http://hdl.handle.net/10668/13606
LA en
DS RISalud
RD Apr 5, 2025